Katie is joined online with Jeremy Skillington of Poolbeg Pharma and David Harel of CytoReason which are new partners in a venture to create opportunities and unlock a bank of unique data.
Data is a critical component in AI systems that model disease and their potential treatments, Harel highlights in the video, and the Poolbeg tie-up is expected to provide unique sets of patient data, potentially allowing for new drug discovery.
Skillington, meanwhile, calls the Cytoreason AI platform "terrific" whilst providing insights into the types of flu patient data being made available in the partnership.